Low response rate reported for Amgen targeted drug in colon cancer trial

An experimental Amgen Inc drug that targets a specific genetic mutation shrank tumors in just one of 12 patients with advanced colorectal cancer who were given the highest dose in a small, early-stage trial, the company said on Saturday.

from Reuters: Health News https://ift.tt/2lO0XjR
via IFTTT